Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are at high risk of developing invasive pneumococcal disease (IPD) with substantial morbidity and mortality. Pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV13) are the primary prevention strategy. The difference between the Japanese and international guidelines is limited except when to start PCV13. However, Japanese data regarding the incidence of IPD after allo-HSCT that include vaccination status are limited. Therefore, we aimed to study the clinical characteristics of patients with IPD following allo-HSCT, focusing on unvaccinated patients. We retrospectively reviewed allo-HSCT recipients between April 2005 and December 2018 at Komagome Hospital. Among 1,091 recipients, 11 (1008/100,000 recipients) developed 13 episodes of IPD. The median period from the first allo-HSCT to the first IPD episode was 686 days (10–3040 days). Ten patients developed IPD before vaccination, and seven of these unvaccinated patients with late-onset IPD were ineligible for vaccination based on domestic guidelines. Although appropriate treatments resulted in a good short-term prognosis, most episodes of IPD developed in unvaccinated allo-HSCT recipients. Our data support the promotion of better adherence to the current guidelines and the importance of pneumococcal vaccination even years after allo-HSCT to protect against late-onset IPD.
Similar content being viewed by others
References
Catterall JR. Streptococcus pneumoniae. Thorax. 1999;54(10):929–37.
Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin N Am. 2015;29(4):679–97.
Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51.
Backhaus E, Berg S, Andersson R, Ockborn G, Malmström P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16:367.
Fukusumi M, Chang B, Tanabe Y, Oshima K, Maruyama T, Watanabe H, et al. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution. BMC Infect Dis. 2017;17(1):2.
van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89–100.
Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008;41(8):743–7.
Torda A, Chong Q, Lee A, Chen S, Dodds A, Greenwood M, et al. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16(5):751–9.
Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117(2):444–50.
Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95(12):3683–6.
Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore). 2007;86(2):69–77.
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–12.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.
The Japan Society for Hematopoietic Cell Transplantation. Guideline for vaccination of hematopoietic cell transplantation (3rd edition) (in Japanese).
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.
Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13(12):1469–76.
Konishi T, Doki N, Nagata A, Yamada Y, Takezaki T, Kaito S, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia. Ann Hematol. 2020;99(1):147–55.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.
Kurosawa S, Doki N, Sekiya N, Senoo Y, Ikuta S, Takaki Y, et al. Pyomyositis caused by Streptococcus pneumoniae after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2017;23(4):250–2.
National Institute of Infectious Diseases. Surveillance of invasive pneumococcal diseases under the Infectious Diseases Control Law, 2013–2017 (in Japanese).
Poutsiaka DD, Munson D, Price LL, Chan GW, Snydman DR. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplant. 2011;46(2):300–7.
Gudiol C, Garcia-Vidal C, Arnan M, Sánchez-Ortega I, Patiño B, Duarte R, et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49(6):824–30.
Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69(2):369–80.
Hammarström V, Pauksen K, Azinge J, Oberg G, Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer. 1993;1(4):195–9.
Robin C, Bahuaud M, Redjoul R, Jeljeli M, Leclerc M, Cabanne L, et al. Antipneumococcal seroprotection years after vaccination in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2019;71(8):e301–7.
Roberts MB, Bak N, Wee LYA, Chhetri R, Yeung DT, Lewis I, et al. Clinical effectiveness of conjugate pneumococcal vaccination in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2020;26(2):421–7.
Acknowledgements
The authors would like to thank the nursing staff at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, for their excellent patient care.
Author information
Authors and Affiliations
Contributions
TK, NS, and ND contributed to data collection and wrote the manuscript. All authors contributed to the clinical care of the patient and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest associated with this article. No external funding was received for this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Konishi, T., Sekiya, N., Otsuka, Y. et al. Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. Int J Hematol 114, 263–270 (2021). https://doi.org/10.1007/s12185-021-03146-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-021-03146-2